Results 201 to 210 of about 3,554 (229)

Pegvisomant in acromegaly: Why, when, how

Journal of Endocrinological Investigation, 2007
N ...
COLAO A., ARNALDI G., BECK PECCOZ P., CANNAVÒ S., COZZI R., DEGLI UBERTI E., DE MARINIS L., DE MENIS E., FERONE D., GASCO, Valentina, GIUSTINA A., GROTTOLI S., LOMBARDI G., MAFFEI P., MARTINO E., MINUTO F., PIVONELLO R., GHIGO, Ezio   +17 more
openaire   +11 more sources

Pegvisomant

Reactions Weekly, 2011
  +5 more sources

Pegvisomant

Reactions Weekly, 2015
  +5 more sources

Pegvisomant therapy for acromegaly

Expert Review of Endocrinology & Metabolism, 2006
Despite traditional, multimodality therapy that consisted of surgery, radiotherapy and medical therapies, many patients with acromegaly could not be adequately treated. Pegvisomant is a novel growth hormone receptor antagonist that became available for the treatment of acromegaly in 2003. This drug is a growth hormone variant that has nine mutations to
openaire   +2 more sources

Pegvisomant

Reactions Weekly, 2019
  +5 more sources

Pegvisomant

Reactions Weekly, 2016
  +5 more sources

Pegvisomant

Drugs of the Future, 1999
null Rabasseda, X., null Leeson, P.
openaire   +1 more source